Accord’s UK Lenalidomide Launch Kicks Off A Year Of Revlimid Competition
UK Generic Launch Comes Ahead Of Expected Rivals Elsewhere In Europe And US
Executive Summary
Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.
You may also be interested in...
Germany’s Pro Generika Sees Steep Revlimid Savings
Generic lenalidomide competitors to BMS’ Revlimid brand have brought the cost of the cancer drug down by as much as 60% in Germany just a couple of months after launch, according to local generics association Pro Generika. However, the industry body has warned, price pressure must not grow so pronounced that the generics market becomes unsustainable.
Accord Adds To Oncology Offering With Orgovyx
Accord Healthcare has struck a European licensing deal with Myovant Sciences for its Orgovyx (relugolix) treatment for advanced hormone-sensitive prostate cancer. The move comes shortly after sister company Accord Biopharma launched the Camcevi (leuprolide) prostate cancer treatment in the US.
Teva Pounces On US Revlimid Opportunity With Four Strength-Offering
Teva has bolstered its oncology offering in the US by moving first on one of the largest small-molecule opportunities in the US: Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) to treat multiple myeloma.